Connect to other sites within the UBM Medica Network
High Cancer Treatment Costs Force Patients to Compromise on Care
A recent survey found that the financial burden of cancer treatment leads many patients to make potentially harmful medical care and lifestyle tradeoffs.
Thymidylate Synthase Predicts Response to Chemo in NSCLC
A new study suggests that expression of the enzyme thymidylate synthase can be used as a predictive marker for lung cancer patients undergoing chemotherapy.
ASCO Endorses Lung Cancer Guidelines for Molecular Testing
ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.
Extended MRD Monitoring Helps Predict Relapse in Pediatric ALL
Monitoring minimal residual disease and real-time quantitative polymerase chain reaction can predict relapse in pediatric acute lymphoblastic leukemia patients.
Pain in Right Arm of 63-Year-Old Patient
A 63-year-old man presents with pain in the right arm. A lesion in the humerus is identified and a biopsy is taken. What is your diagnosis?
Five Healthy Behaviors That May Lower Colorectal Cancer Risk
Adopting a combination of five healthy behaviors is linked to a reduction in the risk of developing colorectal cancer, according to the results of a study.
Medical Decision-Making: Knowledge vs Wisdom
In the field of oncology, we are fortunate to possess a vast and ever-expanding trove of knowledge, and we now have a sufficient foundation of knowledge in many cancers to afford ourselves the luxury of striving to seek wisdom as well.
TERT Promoter Mutations Common in Melanoma
A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, mutations that may be linked with poor prognosis.
Vosaroxin Fails to Improve Overall Survival in AML, but Certain Subgroups Benefit
A phase III trial of vosaroxin failed to meet its primary overall survival endpoint in patients with first relapsed or refractory acute myeloid leukemia.
Neuroendocrine (Small-Cell) Carcinomas: Why They Teach Us Essential Lessons About Prostate Cancer
Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.
By clicking Accept, you agree to become a member of the UBM Medica Community.